Mirum Pharmaceuticals (MIRM) The Citizens Life Sciences Conference 2026 summary

Strategic focus and business model

• Focused on developing and commercializing high-impact rare disease medicines, aiming for efficient development and high-margin commercial returns.

• Achieved strong commercial performance with three approved medicines, targeting $630-650 million in annual revenue.

• Pipeline includes four pivotal readouts over the next 18 months, marking a significant inflection point for the business.

• Business model leverages efficient development and patient finding to drive growth in rare disease markets.

Commercial performance and product growth

• LIVMARLI continues to show strong, steady growth in Alagille syndrome and PFIC, with high patient compliance and persistence.

• Increased genetic testing in adult clinics is driving higher PFIC diagnosis and adoption, with new patients across all age ranges.

• Cholbam and CTEXLI have grown to over $160 million in annual sales, driven by increased awareness and diagnosis efforts.

• Each indication for LIVMARLI is expected to contribute roughly a third to its projected billion-dollar brand status.

Pipeline and clinical development

• Four pivotal readouts expected: PSC (volixibat) in 2Q, bulevirtide phase III and EXPAND (LIVMARLI label expansion) in 4Q, and PBC (volixibat) in 1H next year.

• EXPAND study for LIVMARLI targets ultra-rare cholestatic pruritus indications, with data expected in Q4; biliary atresia is a major subgroup.

• Bulevirtide for Hepatitis D shows strong phase II data, with 100% virologic response and clean safety profile; U.S. and EMA filings expected in the second half of the year.

• Volixibat for PSC and PBC uses pruritus as a primary endpoint, aiming to address significant unmet needs in both populations.